Filing Details

Accession Number:
0001453687-24-000130
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-18 19:28:04
Reporting Period:
2024-11-14
Accepted Time:
2024-11-18 19:28:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1453687 Cartesian Therapeutics Inc. RNAC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
2000282 Milos Miljkovic C/O Cartesian Therapeutics, Inc.
7495 New Horizon Way
Frederick MD 21703
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-11-14 35,000 $3.23 53,273 No 4 M Direct
Common Stock Disposition 2024-11-14 35,000 $16.13 18,273 No 4 S Direct
Common Stock Acquisiton 2024-11-15 20,000 $3.23 38,273 No 4 M Direct
Common Stock Disposition 2024-11-15 20,000 $17.14 18,273 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-11-14 35,000 $0.00 35,000 $3.23
Common Stock Stock Option (Right to Buy) Disposition 2024-11-15 20,000 $0.00 20,000 $3.23
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,528 2031-09-12 No 4 M Direct
30,528 2031-09-12 No 4 M Direct
Footnotes
  1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.465. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The option is currently exercisable for 64,146 shares of Common Stock and becomes exercisable for the remaining 21,382 shares of Common Stock on September 13, 2025.
  4. On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreementand Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series APreferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's CommonStock.